118 results about "INTESTINAL CARCINOMA" patented technology

Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and/or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.

The invention discloses the novel application of clostridium butyricum to drugs, in particular to the application of the clostridium butyricum to the preparation of a drug combination used for preventing and treating intestinal cancer. The novel application comprises the prevention of chronic intestinal disease canceration such as intestinal polyp, Crohn disease, ulcerative colitis, etc., the adjuvant therapy on advanced inoperable intestinal cancer, the adjuvant therapy after the intestinal cancer operation, etc.; the clostridium butyricum is selected from (but is not limited to) clostridium butyricum, CGMCC, and storage serial number 0313.1. In the forms of live bacteria and pharmic receivable different carriers, the clostridium butyricum is made into tablets, capsules, powders, liquid preparations, suppositories, and enemas; the clostridium butyricum can be used for preventing and treating the intestinal cancer for a long time through the methods of oral administration, clysis, injection in the tumor tissue; therefore, the life of a patient suffering from the intestinal cancer is prolonged, and the life quality of the patient suffering from the intestinal cancer is increased.

The invention discloses a medicine for treating gastrointestinal diseases by utilizing biological live bacteria, which is prepared from the following substances: 1 to 6 weight portions of oligoisomaltose, 1 to 6 weight portions of glucose, as well as 1 to 10 hundred million CFU/gram of bifidobacteria, 1 to 10 hundred million CFU/gram of lactobacilli and 1 to 10 hundred million CFU/gram of probiotics which take the total weight of the oligoisomaltose and the glucose as a radix number, wherein the probiotics are at least one of bacillus, lactococcus and enterococcus. The medicine is based on a modern microecology theory, adopts a probiotic live bacteria preparation to treat diseases such as gastritis, gastric ulcer, enteritis, diarrhea, constipation, indigestion, abdominal distension, diarrhea, intestinal cancer, acute and chronic hepatitis, low immunity and the like, and has the advantages of reliable action, broad function, safe use, no any toxic side effect and irritation, convenient administration and carrying and the like.

The invention discloses primer group information of fusobacterium nucleatum, a quantitative PCR (Polymerase Chain Reaction) detection method and application of primer group and method. According to a16S rRNA (ribosomal Ribonucleic Acid) nucleotide sequence and a BLAST (Basic Local Alignment Search Tool) function of bacteria in an NCBI (National Center of Biotechnology Information) database, a fusobacterium nucleatum related primer and V3 to V4 primers are designed according to primer design software Primer Primer 5, and the primers are identified. Genome information of total bacteria is extracted from an excrement sample; the qPCR (quantitative Polymerase Chain Reaction) is carried out through utilizing the primers and the relative content of the fusobacterium nucleatum is calculated andobtained. The detection method is used as a principle and an intestinal micro-ecological detection kit is prepared by utilizing the fusobacterium nucleatum primer. A kit is used for carrying out actual detection and a result shows that the content of the fusobacterium nucleatum in the excrement samples of an intestinal micro-ecological patient and a patient with intestinal cancer is remarkably different from that of normal people. A specific primer of the fusobacterium nucleatum, a rapid and accurate detection method and research and development of an intestinal micro-ecological kit provide methods for knowing the distribution of an intestinal micro-ecology and predicating and primarily screening diseases.

The present invention discloses an in-vitro constructed method for accurately predicting medication of patients with cancers. The method comprises the following steps of: 1) constructing an intestinalcancer organoid, namely culturing a purer intestinal cancer organoid by using cancer tissues obtained by operations or biopsies of patients with colon cancer, patients with rectal cancers or patientswith colorectal cancers; and 2) carrying out a large-flux drug screening test and carrying out a high-flux drug sensitivity detection by taking a micro organ as a unit. The in-vitro constructed method for accurately predicting the medication of the patients with the cancers has advantages that grinding the tissues enables digestion time to be shortened and a digestion degree is also consistent; mild digestive juice reduces damages of the step to cells; different pore diameters are used for filtering to screen the required cells more accurately; immune cells are removed to obtain purer cancercells; a self-made culture medium better conforms to components required by growth of intestinal cancer organs and a culture success rate is increased; and medicine screening is carried out by takingthe organoid as a unit, so that responses of the cancer tissues in vivo after clinical medication are better simulated.

The invention discloses a manufacturing method for a straw mushroom dietary fiber beverage, belonging to the field of beverage processing. The manufacturing method is characterized by adopting processing process flow which comprises the following procedures: (1) preparation of stock solutions: a procedure of preparing a stock solution A by subjecting straw mushroom stems to choosing and cleaning, precooking, beating and coarse filtration, preparing a stock solution B by subjecting wolfberry to impurity removal and soaking, crushing, water extraction and coarse filtration and preparing a stock solution C by subjecting carrot to washing and peeling, softening, beating and coarse filtration; and (2) preparation of a finished product: a procedure of subjecting the stock solution A, the stock solution B and the stock solution C to blending, degassing, homogenization and sterilization so as to obtain the finished product. The invention has the following beneficial effects: the prepared straw mushroom dietary fiber beverage has an orange color, composite flavor unique to straw mushroom, carrot and wolfberry, slippery and smooth mouthfeel and agreeable sour-sweet taste; the prepared straw mushroom dietary fiber beverage has abundant nutrients and a great amount of dietary fiber, can promote gastrointestinal motility and effectively prevent intestinal cancer, gastrointestinal carcinoma, hemorrhoid and the like and is capable of improving human immunity.

The invention provides an anti-virus or/and anti-tumor drug and a preparation method thereof and an application of fenugreek biflavone glycosides for preparing anti-virus or/and anti-tumor drugs. The invention provides the application of the chemical component fenugreek biflavone glycosides in fenugreek seeds as drugs for the first time, and uses the fenugreek biflavone glycosides for preparing anti-virus drugs and anti-tumor drugs for the first time. In vivo and in vitro experiment research shows that fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules of the invention have obvious effect on resisting influenza viruses, and the anti-influenza drug effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules of the invention is superior to the anti-influenza drug effect of the existing Western medicine ribavirin tablets. The anti-HBV effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-HBV effect of kurarinone capsules, and the anti-HIV effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-HIV effect of zidovudine tablets. The fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules have obvious effect on resisting proliferation of liver cancer, gastric cancer, intestinal cancer, lung cancer and cervical cancer cells, and the anti-tumor effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-tumor effect of the existing chemical component preparation hydroxycamptothecine injection.

The invention relates to a humanized intestinal cancer precancerous lesion immortalized epithelial cell line and a construction method and application thereof. The construction method comprises the following steps: firstly, transfecting primarily separated human colorectal adenoma polyp epithelial cells by using an SV40 overexpression lentiviral vector, then performing screening by using puromycin, and finally amplifying the screened cells to obtain the humanized intestinal cancer precancerous lesion immortalized epithelial cell line. The humanized intestinal cancer precancerous lesion immortalized epithelial cell line constructed by the invention overcomes the problems that conventional adenoma polyp cannot be subjected to passage in vitro, is low in cell proliferation and poor in cell activity, and cannot meet the cell passage requirement. According to the invention, the humanized intestinal cancer precancerous lesion immortalized epithelial cell line is established for the first time, an important cell experiment tool is provided for developing an in-vitro experiment of intestinal cancer precancerous lesions, and preclinical researches such as new drug screening and drug effectcomponents are also convenient to develop.

The invention discloses a polypeptide to specifically promote degradation of EGFR (epidermal growth factor receptor) protein, or its derivatives, and application of the polypeptide in the preparationof tumor drugs. An amino acid sequence of the polypeptide is shown as in sequence table SEQ ID No. 1; alternatively, two or more amino acids in the amino acid sequence shown as in the sequence table SEQ ID No. 1 are replaced with side-chain-connectable non-natural amino acids; the derivatives include chimeric peptides that are formed by connecting the polypeptide with cell penetrating peptides. The polypeptide or its derivatives can promote degradation of EGFR protein and inhibit EGFR signal pathway activity; therefore, the polypeptide or its derivatives are applicable to the preparation of tumor drugs. Drugs prepared herein are suitable for treating the tumors, such as lung cancer, intestinal cancer, pancreatic cancer, breast cancer, liver cancer, and glioma.

A method for configuring the eucaryotic expression carrier of cell factor IL-24 includes designing the ascending and descending primers, PCR amplifying begining from the second amino acid in the code at human IL-24 N terminal by using TRAPIL-24 plasmid as template, cutting off target band, purifying it with reagent kit, configuring and determining recombinant plasmid pEGFP-CI-IL-24, respectively enzyme-severing the PCR product and carrier pEGFP by Bgl II and Sal I, purifying them by reagent kit, linking fragment, culturing, cloning, determining and sequencing. The recombinant cell factor Il-24 can be used to treat liver cancer, small intestine cancer and melanoma.

The invention relates to a traditional Chinese medicine with special anti-cancer effect for the treatment of adenocarcinoma classified by cytology, which is prepared by the traditional Chinese medicine raw materials with the weight percentage: 14 percent of ginseng, 13 percent of sanchi, 13 percent of prepared turtle shell, 1 percent of artificial musk, 13 percent of prepared turtle shell, 13 percent of adulterated pangolin scales, 15 percent of Chinese eaglewood, 13 percent of herba violae, 1 percent of gamboge and 4 percent of toad skin; the traditional Chinese medicine raw materials are ground into traditional Chinese medicine powder; the traditional Chinese medicine has the effects of strengthening body resistance, strengthening vital qi to eliminate pathogenic factor, nourishing yin, suppressing hyperactive yang, clearing heat, removing toxin, softening, resolving hard mass, activating blood circulation, removing blood stasis, enhancing human immunity, having vitality to kill cancer cells and having no evident toxicity to normal cells, thus being used for the treatment of adenocarcinoma, carcinoma of stomach, intestinal carcinoma, breast carcinoma, liver carcinoma and peripheral pulmonary carcinoma.

The invention relates to a pharmaceutical composition containing an insulin-like growth factor-I receptor inhibitor and a histon deacetylase (HDAC) inhibitor and an application thereof in preparing medicines for treating intestinal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer or prostate cancer. The pharmaceutical composition of the invention has obvious synergistic effect, thus improving curative effect of medicines, lowering administration dosage and reducing occurrence of side effect.

The invention provides an application of a composition of a clostridium butyricum and bifidobacterium dual live bacteria preparation and an anticancer medicament in preparation of a medicament for treating intestinal cancer. The aim of treating the intestinal cancer is fulfilled by combining the anticancer medicament and the clostridium butyricum and bifidobacterium dual live bacteria preparation; and the composition of the clostridium butyricum and bifidobacterium dual live bacteria preparation and the anticancer medicament has an effective effect of treating the intestinal cancer, so that the lives of intestinal cancer patients are prolonged, and the living quality of the intestinal cancer patients is improved.

The invention relates to a novel bisamides derivative and a preparation method and an application thereof. A general formula of the novel bisamides derivative is shown as follows, and each group is shown in patent claims. The novel bisamides derivative has good antineoplastic activity, such as lung cancer, liver cancer and intestinal cancer. partial compound has higher in-vitro inhibition rate on three cancer cell bacterial strains than a control sample 5-fluorouracil, partial compound has in-vitro inhibition rate on lung adenocarcinoma (A549), liver cancer(Bel7402) and intestinal cancer (HCT-8) three cancer cell bacterial strains as high as more than 85%, and most compound has in-vitro inhibition rate on liver cancer (Bel7402) cell bacterial strain as high as more than 80%. The novel bisamides derivative can possibly be an antitumor drug.

Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma/carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma.

The invention belongs to the technical field of medical detection application and discloses a method for detecting cytokines secreted by specific T cells in lung cancer or intestinal cancer. A systemis composed of a detection sample, a target, a stimulation antigens and/or positive control antigens of the detection sample and conventional reagents of the detection sample. The sample in the detection system is mononuclear cells after peripheral blood of a lung cancer or intestinal cancer patient is separated, and cytokines secreted by the specific T cells are detected through a plurality of rounds of stimulation of polypeptide. According to the method, the mononuclear cells are induced into DC cells; the DC cells and the T cells are co-cultured; after the polypeptide is added and three rounds of stimulation is carried out, the cytokines secreted by the specific T cells are detected; and under the condition that detection sensitivity is not influenced, detection time of the whole systemis reduced. According to the detection system provided by the invention, an application method is simple, rapid and efficient. The detection time is reduced. Detection efficiency is improved. The detection system provided by the invention is wide in application range and has huge market value.

The invention discloses a standardized culture medium for three-dimensional culture of intestinal and intestinal cancer tissue organs and a culture method. The standardized culture medium comprises atleast one or more of a reagent A, a reagent B and a reagent C; wherein the reagent A comprises one or more of Nacetylcysteine, Y-27632, A8301, a recombinant human epidermal growth factor and gastrin;and the reagent B is prepared from one or more of R-spodin1, Noggin, nicotinamide and SB202190, and the reagent C comprises Wnt-3A. According to the culture medium disclosed by the invention, aimingat the growth characteristics of adult stem cells in intestinal tissues, various growth factor components are selected for blending, and by optimizing the proportion of growth factors in the culture medium, the adult stem cells of intestines and cells of intestinal cancer can effectively form organoids of intestines and organoids of intestinal cancer respectively in a three-dimensional culture environment.

The invention provides a benzyloxy aromatic ring structure compound represented by a general formula (I), a stereoisomer, an enantiomer or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the same, and uses thereof. The compound shown in the general formula (I) can be used for preparing a small-molecule inhibitor of PD1/PDL1 interaction, and can be used for preventing and/or treating diseases related to PD1/PDL1 interaction, especially cancers, such as non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, local advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell cancer, prostate cancer, liver cancer, intestinal cancer, stomach cancer, multiple myeloma, mantle cell lymphoma, diffuse large B cell lymphoma, liver cancer, hodgkin lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and the like.

The invention belongs to the field of pharmaceutical chemistry and relates to a 9,10-anthraquinone compound and a pharmaceutical application thereof, in particular to the 9,10-anthraquinone compound and the application thereof in the preparation of a phosphoglycerate mutase inhibitor and in the preparation of drugs for treating cancer. In particular, the invention discloses the application of the9,10-anthraquinone compound shown in the structure of a formula I, pharmaceutically-acceptable salts thereof, or a pharmaceutical composition taking the 9,10-anthraquinone compound as an effective active ingredient in preparing drugs for preventing and treating tumors. The compound can inhibit phosphoglycerate mutase activity and reduce cell metabolism level, and can be used for treating diseasessuch as solid tumors and blood tumors, and the tumors involved are pancreatic cancer, lung cancer, liver cancer, gastric cancer, esophageal cancer, intestinal cancer, breast cancer, cervical cancer, leukemia and melanoma.

The invention relates to an RT-PCR kit and a method for evaluating the concurrent intestinal cancer susceptibility of a hyperglycemia population by using the kit, belonging to the technical field of real-time fluorescence quantitative reverse transcription polymerase chain reaction kit development and human pathology combination. RT-PCR primers for detecting the transcriptional level of GRP78 mRNA in serum include a primer F: 5'-CCCGTCCAGAAAGTGTTG-3' and a primer R: 5'-CAGCACCATACGCTACAG-3'. The invention establishes a method for detecting GRP78 mRNA in peripheral vein serum by using the specific primers; and a quantitative PCR amplification technology is adopted in the method, so that the sensitivity for detecting GRP78 mRNA is greatly improved, and enough information can be obtained in extremely few specimens.

The invention belongs to the field of traditional Chinese medicine technologies, and especially relates to a traditional Chinese medicine for treating intestinal cancer and a preparation method of the traditional Chinese medicine. The traditional Chinese medicinal is prepared from the following traditional Chinese raw materials in parts by weight: 5-10 parts of common camptotheca fruit, 5-8 parts of Chinese actinidia root, 5-8 parts of hedyotis diffusa, 3-5 parts of bearded scutellaria, 5-8 parts of marsdenia, 5-8 parts of cynanchum bungei, 1-3 parts of Chinese fanpalm seed, 5-8 parts of cephalotaxus fortunei root, 3-5 parts of sophora wood ear, 2-3 parts of sparganium, 2-3 parts of curcuma, 3-5 parts of akebia fruit, 3-5 parts of barley shoot, 2-3 parts of citron, 3-8 parts of herb of scape-like sage, 3-8 parts of salvia scapiformis hance and 3-8 parts of astragali. The traditional Chinese medicine for treating intestinal cancer is water decoction. The traditional Chinese medicine disclosed by the invention can inhibit tumor reproduction, control the spread and metastasis of tumor, boost immunity by virtue of functions of clearing heat and removing toxicity, rectifying qi and transforming stagnation, dispelling stasis and removing stagnancy of the traditional Chinese medicine, and the traditional Chinese medicine for treating intestinal cancer can also relieve pain and eliminate tumor, ease pain of patients and save lives of patients.

The invention belongs to the technical field of molecules and cellular biology, and particularly relates to a constructing method of a mouse intestinal epithelium pit cell line. The method comprises the steps that a single cell suspension of pit epithelium cells is prepared through a special separation method, cellular immortality is conducted after cell adherence. The form of intestinal epithelium primary cells is well maintained by the cell line, and high proliferation capability is achieved. Characteristic organ structures can be formed in three-dimensional culturing conditions, it is indicated by specific staining that cells which form the structure comprise multiple intestinal epithelium differentiated progeny. Pit cells of an established line can only grow in primary culturing conditions still, and the pit cells can be applied to the establishing of a mouse intestinal epithelium in vitro multi-dimensional study model which is used for studying intestinal physiologic functions andpathological mechanisms including infection, carcinogenesis and the like, and tools and platforms are provided for treatment targets and medicine screening and evaluating of intestinal diseases including intestinal cancer.

The invention relates to the technical field of traditional Chinese medicine, and discloses a composition for a patient to use in the postoperative adjuvant chemotherapy stage of intestinal cancer radical treatment and application, and the composition comprises the following components by weight: 15-60g of Astragalus membranaceus, 10-30g of radix pseudostellariae, 10-30g of rhizoma pinellinae praeparata, 10-30g of rhizoma atractylodis, 20-30g of poria cocos and 15-30g of sculellaria barbata. For a patient with nausea and vomiting, the ginger and the fructus amomi are added when the body is cold, and the coptis chinensis and the bamboo shavings are added when the body is hot; for diarrhea patients, smoked plums and schisandra chinensis are added; for anorexia patients, hawthorn, medicated leaven and malt are added; for people with alopecia, polygonum multiflorum, eclipta and glossy privet fruit are added; for patients with mouth and tongue sores, coptis chinensis and fructus gardeniae are added; and lumbricus and centipede are added for patients with numbness of limbs. The composition provided by the invention can relieve toxic and side effects of patients caused by adjuvant chemotherapy and improve the living quality of the patients aiming at adjuvant chemotherapy patients after intestinal cancer radical operation.

Aiming at the difficult problem that clinical application of existing hypoxia inducible factor (HIF)-1 alpha is difficult to achieve, the invention provides an intestinal cancer cell strain expressing an HIF-1 alpha gene efficiently, wherein the bacterial strain is preserved in a common microorganism center of China microorganism strains preservation and management committee and the preservation number is CGMCC No. 5261. The intestinal cancer cell strain expressing the HIF-1 alpha gene efficiently can be used in the fields such as research of an intestinal cancer mechanism and sifting of cancer treatment medicine, and provides a quite valuable tool for the basic and clinic research.